Archives
-
DPP8/9 Inhibitors and CARD8 Inflammasome Activation
2026-10-06
Johnson and colleagues show that resting human and rodent lymphocytes can undergo DPP8/9 inhibitor-induced pyroptosis, extending inflammasome biology beyond its traditional focus on myeloid cells. The study identifies CARD8 as a key mediator in human T cells and demonstrates that activation state and species strongly influence susceptibility.
-
BX795: Evidence, Applications, and Limitations
2026-10-06
BX795 is commonly described as a PDK1 inhibitor, but supplied evidence also implicates TBK1 and IKKε. This overview distinguishes supplier-reported biochemical and cell-based findings from the broader methodological evidence in Schwartz’s dissertation, emphasizing pathway interpretation, response metrics, evidence strength, and applicability limits.
-
5-Azacytidine and DNA Damage in Myeloma Cells
2026-10-05
This 2007 study showed that 5-azacytidine acts against multiple myeloma cells through ATR-associated DNA double-strand break responses and both caspase-dependent and independent apoptosis. Its findings also identified synergistic cytotoxicity with doxorubicin and bortezomib, while remaining limited to preclinical cell-based evidence rather than clinical efficacy.
-
NAT1–ENO1–Lactate Signaling in Colorectal Cancer
2026-10-05
A 2026 MedComm study identifies a NAT1–ENO1–lactate–TRAF6 pathway that connects tumor glycolysis with PD-L1 stability and immune escape in colorectal cancer. Its multi-layered evidence suggests that metabolic state can influence checkpoint biology, while also highlighting the need for validation across tumor genotypes, immune contexts, and patient cohorts.
-
DiscoveryProbe™ Immunology/Inflammation Library
2026-10-04
The L1042 immunology inflammation compound library is a 295-compound small-molecule collection marketed for immunology and inflammation research. Available information supports product identity and intended conceptual scope, but no matched paper evidence or independent performance results are available.
-
BCB Nanoassembly, Cuproptosis, and Bone-Targeted Therapy
2026-10-03
The reference study presents BCB, a baicalein–copper coordinated nanoassembly combined with a boron-dipyrromethene photosensitizer, for integrated chemodynamic, photodynamic, and cuproptosis-based cancer therapy. In preclinical melanoma models, the platform promoted glutathione depletion, reactive oxygen species generation, mitochondrial injury, and selective accumulation in intramedullary tumor sites, although its translational relevance remains unestablished.
-
C34 TLR4 Inhibitor: Mechanism, Evidence & Use
2026-10-02
C34 is a selective small-molecule TLR4 inhibitor for studying LPS-associated inflammatory signaling. The product dossier reports activity near 10 μM in vitro and approximately 1 mg/kg in animal models, while peer-reviewed work uses C34 as a TLR4 reference inhibitor in microglial experiments.
-
Taxus chinensis Fruit, TLR4, and Neuroinflammation
2026-10-01
A Journal of Ethnopharmacology study links Taxus chinensis fruit extract with reduced aging-related behavioral changes and neuroinflammation through suppression of microglial TLR4/NF-κB/NLRP3 signaling. Its integrated mouse, BV2 microglia, UPLC-MS/MS, and molecular docking design provides a useful framework for connecting botanical constituents with inflammatory pathway modulation while highlighting important limits in causal interpretation.
-
Methylprednisolone as a Bone-Injury Model Lever
2026-10-01
Methylprednisolone is a synthetic glucocorticoid receptor agonist that connects inflammatory signaling with skeletal remodeling. This article presents a causal assay framework built around solubility, multiscale endpoints, and evidence from glucocorticoid-induced osteonecrosis research.
-
Angiotensin Peptides and SARS-CoV-2 Spike–AXL Binding
2026-09-30
A 2025 study found that naturally occurring angiotensin fragments can increase SARS-CoV-2 spike protein binding to host receptors, with the strongest effects observed for peptides containing N-terminal deletions. The work connects renin–angiotensin signaling with viral-entry biochemistry while emphasizing that the evidence remains based on protein-binding assays rather than clinical or infection models.
-
L1042 immunology inflammation compound library
2026-09-30
The DiscoveryProbe™ Immunology/Inflammation Compound Library provides a structured panel of 295 small molecules for immunomodulator screening, inflammation target validation, and phenotypic assay development when a single pathway or compound class is insufficient. It is intended for controlled research workflows, not for diagnostic use, clinical treatment decisions, or assuming activity in a specific model without assay-specific confirmation.
-
JSH-23: Reading NF-κB Beyond Nuclear Translocation
2026-09-29
JSH-23 is an NF-κB inhibitor that separates p65 nuclear transcription from upstream IκB degradation. This article presents a cell-type and assay-design framework for using JSH-23 in inflammation research and macrophage–NLRP3 studies.
-
HNRNPU K181 Lactylation Rewires Serine Metabolism
2026-09-29
This Advanced Science study identifies HNRNPU lysine 181 lactylation as a metabolic-to-post-transcriptional signaling mechanism in cervical cancer. The modification stabilizes HNRNPU, promotes PHGDH mRNA regulation, and sustains serine biosynthesis, while competition with NAA50-mediated acetylation creates a regulatory switch with potential therapeutic relevance.
-
PEP Restricts cGAS–STING Inflammation in Aging
2026-09-28
A 2026 Nature Aging study identifies phosphoenolpyruvate (PEP) as an adaptive metabolic brake on cGAS–STING-driven inflammation. Its longitudinal, mechanistic, and disease-model evidence connects age-dependent PEP dynamics with inflammaging, healthy aging, neuroinflammation, and cognitive function.
-
Entamoeba Prx Activates Macrophage Autophagy
2026-09-28
The study reports that peroxiredoxin from Entamoeba histolytica can stimulate autophagy in macrophages, with evidence implicating TLR4–TRIF signaling and a functional C-terminal region of the parasite protein. The findings connect a parasite antioxidant enzyme to host-cell responses, while highlighting the need to distinguish autophagosome formation from complete autophagic flux and to test consequences during infection.